The Second Affiliated Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang Province, China.
Eur Rev Med Pharmacol Sci. 2017 Jul;21(3 Suppl):47-51.
To investigate the expression of leukemia-related protein 16 (LRP16), proliferating cell nuclear antigen K-67 (Ki67) and epidermal growth factor receptor-1 (EGFR-1) in breast cancer tissue and to explore the correlation between the expression of those proteins and breast cancer clinical pathologic factors and prognosis.
The expressions of LRP16, Ki67 and EGFR in breast cancer tissues of 86 cases were detected by the immunohistochemical method and the correlations between the expression of LRP16, Ki67 and EGFR and clinical pathologic factors and prognosis were investigated.
Positive expression rates of LRP16, Ki67 and EGFR in breast cancer tissue were 52.3%, 70.9% and 16.3%, respectively. There was no statistical difference in the expression of RP16, Ki67 and EGFR between different age groups (p>0.05). The expression of LRP16 was correlated with clinical stage, histological grade, tumor size and lymphatic metastasis (p<0.05); the expression of Ki67 was correlated with clinical stage, histological grade, tumor size and lymphatic metastasis (p<0.05); the expression of EGFR was correlated with histological grade (p<0.05). Comparison of postoperative local recurrence and metastasis time between LRP 16 positive group and negative group showed statistically significant difference (p<0.05); comparison of postoperative local recurrence and metastasis time between Ki67 positive group and negative group also showed statistically significant difference (p<0.05); comparison of postoperative local recurrence and metastasis time between EGFR positive group and negative group showed no statistically significant difference (p<0.05).
Detection of expression levels of LPR16, Ki67 and EGFR in breast cancer tissue improves the understanding of biological behaviors of breast cancer, which in turn provide clinical guidance in diagnosis, treatment and prognosis assessment.
研究白血病相关蛋白 16（LRP16）、增殖细胞核抗原 K-67（Ki67）和表皮生长因子受体-1（EGFR-1）在乳腺癌组织中的表达，探讨这些蛋白的表达与乳腺癌临床病理因素及预后的关系。
采用免疫组化法检测 86 例乳腺癌组织中 LRP16、Ki67 和 EGFR 的表达，探讨 LRP16、Ki67 和 EGFR 的表达与临床病理因素及预后的关系。
乳腺癌组织中 LRP16、Ki67 和 EGFR 的阳性表达率分别为 52.3%、70.9%和 16.3%。不同年龄组 LRP16、Ki67 和 EGFR 的表达无统计学差异（p>0.05）。LRP16 的表达与临床分期、组织学分级、肿瘤大小和淋巴转移有关（p<0.05）；Ki67 的表达与临床分期、组织学分级、肿瘤大小和淋巴转移有关（p<0.05）；EGFR 的表达与组织学分级有关（p<0.05）。LRP16 阳性组与阴性组术后局部复发和转移时间比较差异有统计学意义（p<0.05）；Ki67 阳性组与阴性组术后局部复发和转移时间比较差异有统计学意义（p<0.05）；EGFR 阳性组与阴性组术后局部复发和转移时间比较差异无统计学意义（p<0.05）。
检测乳腺癌组织中 LPR16、Ki67 和 EGFR 的表达水平，有助于了解乳腺癌的生物学行为，为临床诊断、治疗和预后评估提供指导。
